Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis.

Yin, Juntao; Chen, Yangyang; Li, Yang; Zhang, Xingwang; Wang, Chaoyang

Yin, Juntao; Chen, Yangyang; Li, Yang; Zhang, Xingwang; Wang, Chaoyang.

Afiliação

Yin J; Department of Pharmacy, Huaihe Hospital, Henan University, Kaifeng, Henan, China.
Chen Y; Cardiology, Huaihe Hospital, Henan University, Kaifeng, Henan, China.
Li Y; Department of Pharmacy, Huaihe Hospital, Henan University, Kaifeng, Henan, China.
Zhang X; Department of Pharmaceutics, School of Pharmacy, Jinan University, Guangzhou, Guangdong, China.
Wang C; Evidence-Based Medicine Center, Department of Medicine, Henan University, Zhengzhou, Henan, China.

Hum Vaccin Immunother ; 18(6): 2119763, 2022 Nov 30.

Article em En | MEDLINE | ID: mdl-36161976

Assuntos

COVID-19; Neoplasias; Humanos; Vacinas contra COVID-19; COVID-19/prevenção & controle; Estudos Prospectivos; Soroconversão; Vacinação; Anticorpos Antivirais

Palavras-chave

COVID-19; SARS-CoV-2; immunogenicity; meta-analysis; solid cancer; vaccine

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 / Neoplasias Tipo de estudo: Observational_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Hum Vaccin Immunother Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google